• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Serotonin reuptake inhibitors: pros and cons (Proceedings)

October 1, 2011
Sharon Crowell-Davis, DVM, PhD, DACVB

New SSRIs and SNRIs are typically very expensive. We usually use the older ones in veterinary medicine because of cost.

Abbreviations

  • SRI-Serotonin Reuptake Inhibitor

  • SSRI-Selective Serotonin Reuptake Inhibitor

  • SNRI-Serotonin and Norepinephrine Reuptake Inhibitor

  • TCA-Tricyclic Antidepressant (a family of SNRI's)

 

Cost: Old vs. New

  • New SSRI's and SNRI's are typically very expensive

  • We usually use the older ones in veterinary medicine because of cost issues

 

Action-SSRI's

  • Inhibition of serotonin reuptake.  This increases serotonergic neurotransmission by allowing serotonin molecules to act for extended periods of time.Chronic administration causes decreased numbers of serotonin receptors, as well as altered function of various sertonin receptors.

 

Action-SNRI's

Advertisement

  • 5-HT reuptake inhibition and NE reuptake inhibition

  • Chronic administration causes decreased numbers of b-adrenoceptors and serotonin receptors, as well as altered function of various sertonin receptors.

  • TCA's also have a-1 adrenergic antagonism, are anticholinergic and antihistaminic

 

Uses in dogs and cats

  • Anxiety and disorders motivated by anxiety, e.g. urine marking

  • Aggression

  • Compulsive Disorder, e.g. tail-chasing, lick granuloma

 

Ssri's

  • Side Effects: Sedation, Anorexia, Gastrointestinal signs, Anxiety, Irritability, Insomnia, Aggression, Decreased libido

 

Ssri's

  • Slow onset of action

  • Give daily, not “as needed”

  • Can require 4-8 weeks to take full effect

  • Metabolized in liver

  • Excreted through kidneys

  • May have 1-4 week latency to effect

  • Long t1/2

 

Citalopram hydrobromide

  • DOGS: 0.5-1.0 mg/kg q24h

 

Fluoxetine hydrochloride (prozac®, reconcile™)

  • DOGS: 1.0-2.0 mg/kg q24h

  • CATS 0.5-1.5 mg/kg q24h

 

Contraindications

  • Reduce dose with patients with hepatic or kidney impairment

  • Use cautiously with patients with diabetes mellitus (may decrease blood glucose)

  • History of seizures

  • Use cautiously with TCA                       

  • DO NOT use with MAOI

 

 

Pharmacokinetics

  • Well absorbed after oral administration

  • Metabolized by cytochrome P450 enzyme system to norfluoxetine, which is active

  • In dogs, the elimination half-life of fluoxetine is 6-7 hours

 

Half-life of norfluoxetine is about 2 days

  • Reconcile™End of 8 weeks

  • 73% of dogs on Reconcile showed improvement

  • 51% of dogs on placebo showed improvement

 

Fluoxetine in Cats (Pryor et al. 2001)

  • Cats treated with fluoxetine showed a significant decrease in spraying by the second week, and continued to exhibit a decreased frequency through the end of an 8 week study.

 

Paroxetine hcl Paxil®

  • CATS: 0.5-1.0 mg/kg

  • DOGS: 0.5-1.0 mg/kg

 

Sertraline (zoloft®)

  • CATS: 0.5-1.0 mg/kg

  • DOGS: 0.5-4.0 mg/kg

 

Tca's: tricyclic antidepressants

  • Named after chemical structure

  • Use in animals as for SSRI's

 

Tertiary amines

  • Have two methyl groups at the end of their side chain.

  • More potent inhibition of 5-HT uptake

  • More potent a-adrenergic, cholinergic, and histaminergic receptor blockade

  • Significant sedative effects

  • Amitriptyline, Clomipramine, Doxepin, Imipramine

 

Secondary amines

  • One methyl group at the end of the side chain

  • More potent inhibition of NE reuptake

  • Desipramine, Nortriptyline

 

Biochemical activity

Effects-Therapeutic Norepinephrine Serotonin Decrease general arousal Regulate mood states Increase attention Decrease fear responses Decrease mood reactivity Decrease or increase feeding behavior Increase stress response modulation Decrease impulsive behavior

 

 

Effects - a-Adrenergic antagonism

  • Orthostatic hypotension, Dizziness, Syncope, Sedation, Vasoconstriction,  Smooth muscle contraction

 

Effects - anticholinergic

  • Urinary retention, Dry mouth, Dental pathology, Stomatitis, Mydriasis,¯ Tear production, Impaired visual accommodation, Blurred vision, Bronchodilation

 

Effects – anti-histaminic

  • Anti-pruritic effect,Sedation, Anti-ulcer activity, Weight gain

 

Cardiovascular Effects: Much more profound in humans than in dogs and cats

  • ECG Assessment in Dogs

  • Research on cardiac function in dogs given amitriptyline and clomipramine

  • No ECG changes between pre and post-treatment

  • No differences between untreated and treated dogs

  • Gastrointestinal Effects: Vomiting, Diarrhea, Anorexia,Constipation

  • Behavioral: Anxiety, Restlessness, Agitation, Sleep disorders, Fatigue, Headache, Ataxia

  • Other Effects: Lowered seizure threshold, Altered blood glucose levels,Bone marrow suppression

  • Bitter taste→Difficulty in medicating animals-Helps prevent overdosing

 

Dose management

  • 2 – 4 week latency to effect, sometimes longer

  • Give daily or b.i.d., not “as needed”

  • Stabilize for 1 – 2 months

  • Gradual withdrawal

  • Certain conditions require long-term treatment

  • Metabolized in liver

  • Cleared primarily through urine

 

Pharmacokinetics

  • Individual variation in metabolic rate

  • “Poor metabolizers”

  • Hepatic P450 enzymes

  • Decreased renal clearance in human geriatric patients

  • Clinical experience→Some dogs appear to be poor metabolizers

 

Drug interactions

  • MAOIs, Anticholinergics, Sympathomimetics, Cardiac toxicity, Thyroid supplements, Anti-thyroid agents, Agranulocytosis

  • Cytochrome P450 competition: Antidepressants, Antipsychotics, Psychostimulants

  • Precautions: Glaucoma, Urinary retention, Cardiac disease, Thyroid disease, Seizure disorder, Adrenal tumors, Liver disease, Kidney disease, Pregnant female, Lactating female

 

Tca toxicity

  • Narrow therapeutic index in humans

  • 1 week supply for a dog could be fatal to a human

  • Toxicity at 2-6 x normal clinical dose

  • 5% human fatality rate for overdoses

 

Toxicity in Companion Animals

  • Illinois Animal Poison Information Center: 456 calls (1985-1989)

  • Accidental ingestion of TCAs

  • > 7% fatality rate

  • ³ 15 mg/kg PO potentially fatal

 

Treatment

  • No specific antidote, Emetics not indicated except in first 30 minutes, Supportive care, Airway support, Gastric lavage, Activated charcoal, Diazepam for seizures, Na bicarbonate for acidosis

  • Physostigmine IV helps with CNS and cardiac toxic effects in humans

 

 

Amitriptyline (elavil)

  • DOG                       1-6 mg/kg q12-24 h

  • CAT                        0.5-2.0 mg/kg q12-24 h

 

TCA with most potent H1 blockade

  • Dogs: Significantly less effective than clomipramine for compulsive disorder (Overall and Dunham 2002)

  • Used effectively in cats for Idiopathic cystitis, Excessive vocalization in a cat, Psychogenic alopecia

 

Clomipramine (anafranil, clomicalm™)

  • DOG                       1-3 mg/kg q12 hr

  • CAT                        0.25-2.0 mg/kg q24h

 

Pharmacokinetics

  • Most serotonin selective of the TCA's

  • Metabolites: Desmethylclomipramine

  • Higher concentration than parent compound in humans, but not in dogs

  • Potent NE REuptake inhibitor

 

Comparative pharmacokinetics

  • Clomipramine: Desmethylclomipramine concentration

  • Dog 3:1

  • Human 1:2.5

  • May be reason adverse events more common in humans

  • Desmethylclomipramine has stronger anticholinergic activity than clomipramine

  • Most common side effects: Mild sedation, usually transient, Vomiting, Appetite changes

  • Also mydriasis and urinary retention

 

Administration: Single or divided dose

  • 2-4 mg/kg (total daily label dose)

  • With or without food (administration with food may reduce incidence of emesis)

  • In practice, I often go up to 6 mg/kg tdd

  • In clinical trials for Separation Anxiety, 75% of dogs were considered improved by their owners after one month of dosing

 

Higher doses more effective than lower doses (Simpson 1997; King et al. 2000)

  • I only use low dose (1 mg/kg b.i.d.) in geriatric patients or patients with mild compromise of liver or kidney function

  • Stereotypies/Compulsive Disorder

  •                                                            

Doxepin (sinequan)

  • CAT        0.5-1.0 mg/kg q12h

  • DOG       3.0-5.0 mg/kg q8-12h

 

Imipramine

  • CAT        0.5-1.0 mg/kg q12-24h

  • DOG       0.5-2.0 mg/kg q8-12h

  • Anti-enuretic effect: In humans is used for depression and childhood enuresis

  • Canine submissive urination, Canine excitement-induced urination, Urinary incontinence (dogs and cats)

  • Mild OCD

 

Nortriptyline (pamelor®)

  • CAT        0.5-2.0 mg/kg q12-24h

  • DOG       1.0-2.0 mg/kg q12h

Related Content:

Behavior
To refer or to not refer
To refer or to not refer
Discussing the significance of puppy socialization with clients
Discussing the significance of puppy socialization with clients
Touching the untouchables: The first reactive referral center for pets with behavioral challenges
Touching the untouchables: The first reactive referral center for pets with behavioral challenges

Advertisement

Latest News

To refer or to not refer

Advice panel for women interested in the veterinary field

AVMA president set to testify before Congress

New Hawaii-based pet CBD brand launches

View More Latest News
Advertisement